Thus, the DETECTION trial will involve melanoma patients with stage IIB/IIC disease with BRAF/NRAS/TERT promoter mutations, surgically resected; the patients will be analyzed for the presence of ctDNA, and those positive will be randomized 1:1 to continue routine follow-up and therapy with either the clinical option under investigation or treatment with nivolumab [47]. This evidence concerns the gene TERT and melanoma.